Clinical trials: Adjuvant Treatment
HIV Infections
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.
- Trial name
- NCT00002359
- Testing
- HIV-1 Immunogen
- Where
- 54 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- The Immune Response Corporation
Endometrial Cancer
Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor tissue. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006027
- Testing
- cisplatin, paclitaxel, adjuvant therapy
- Where
- 29 sites in United States, Norway
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients…
- Trial name
- NCT00003357
- Testing
- GM2-KLH vaccine, QS21
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The goal of this clinical trial is to learn if tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy works to treat for resectable stage II-IIIB driver gene-negative NSCLC.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
- Trial name
- NCT06977828
- Testing
- tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adrenocortical Carcinoma
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Study Rationale Adrenocortical carcinoma (ACC) is a very rare disease with a high risk of relapse after radical surgery. The efficacy of adjuvant mitotane treatment is suggested by a retrospective multicenter international study…
- Trial name
- ADIUVO (NCT00777244)
- Testing
- MITOTANE
- Where
- 28 sites in United States, Canada and 5 more
- Volunteers
- 200 people
- Sponsor
- University of Turin, Italy
Melanoma
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of…
- Trial name
- NCT03897881
- Testing
- mRNA-4157, Pembrolizumab
- Where
- 23 sites in United States, Australia
- Volunteers
- 267 people
- Sponsor
- ModernaTX, Inc.
Breast Cancer
Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01424865
- Testing
- fluorescence in situ hybridization, immunohistochemistry staining method, immunologic technique
- Volunteers
- 1,874 people
- Sponsor
- NSABP Foundation Inc
Fasciitis, Plantar
Efficacy of Focused Shock Waves Combined With Adjuvant Therapy With Tendon Supplement
Physical treatment with focused shock waves is effective in the treatment of tendonitis. Food supplements could facilitate the healing of tendinopathies when combined with shock wave therapy.
- Trial name
- NCT04664712
- Testing
- Tendisulfur Pro, Focused shock wave
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Breast Neoplasms
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way.
- Trial name
- NCT01740271
- Testing
- Epirubicin
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer, Early-stage Breast Cancer
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a…
- Conditions
- Breast Cancer, Early-stage Breast Cancer, Ductal Carcinoma in Situ, DCIS
- Trial name
- H-ASSIST (NCT06902311)
- Testing
- Breast Radiotherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell…
- Trial name
- NCT05239728
- Testing
- Belzutifan, Pembrolizumab
- Where
- 285 sites in United States, Australia and 30 more
- Volunteers
- 1,800 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma
A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
The main purpose of this observational study with Oxaliplatin onkovis is to determine the number of treatment cycles and the quantity of Oxaliplatin onkovis needed for this purpose under the special circumstances of ambulant…
- Trial name
- NCT01942200
- Where
- 3 sites in Germany
- Volunteers
- 383 people
- Sponsor
- Onkovis GmbH
Newly Diagnosed Triple-negative Breast Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer
This study is a multicenter, randomized controlled phase III clinical trial. The aim of this study is to observe the efficacy and safety of PD-1 inhibitors combined with capecitabine, PD-1 inhibitors alone, or capecitabine alone…
- Trial name
- CREATE (NCT07869628)
- Testing
- Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine
- Volunteers
- 852 people
- Sponsor
- Shandong Cancer Hospital and Institute
Pancreatic Cancer
Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)
Pancreatic cancer is one of the deadliest tumor types of the alimentary system. Resection is the only curable method to treat pancreatic cancer.
- Trial name
- NCT02461836
- Testing
- Gemcitabine, SBRT
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Thyroid Neoplasms
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
- Trial name
- NCT00279721
- Testing
- IMRT
- Volunteers
- 40 people
- Sponsor
- Alberta Health services
Endometrial Cancer
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
The goal of this clinical trial is to establish the fraction of patients that achieve a major pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of informing a follow-up randomized trial.
- Trial name
- PAM-II (NCT06180733)
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- University Medical Center Groningen
Gastrointestinal Stromal Tumors
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Approximately 95% of GISTs are positive for KIT (CD117)-the receptor for stem cell factor (SCF).
- Trial name
- INV555 (NCT01172548)
- Testing
- imatinib mesylate
- Where
- 29 sites in Algeria, Egypt and 10 more
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Carpal Tunnel Syndrome, PRP
PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome
This study assesses the potential benefit of adjuvant platelet-rich plasma (PRP) with carpal tunnel release (CTR) for patients with severe carpal tunnel syndrome (CTS).
- Trial name
- NCT04811287
- Testing
- Carpal Tunnel Release with Platelet-Rich Plasma, Carpal Tunnel Release without Platelet-Rich Plasma
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Michael Fredericson, MD
Cholangiocarcinoma, Intrahepatic
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.
- Trial name
- NCT04782804
- Testing
- Capecitabine, PD-1 Antibody（Tislelizumab）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Pompe Disease
Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
evaluate if beta 2-adrenergic agonist can have adjuvant effect to patients with infantile-onset Pompe disease under enzyme replacement therapy
- Trial name
- NCT02405598
- Testing
- Salbutamol
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.